X

Trial Profile

A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exemestane (Primary) ; Fulvestrant (Primary) ; I 022 (Primary) ; Letrozole (Primary)
Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer
Focus Therapeutic Use
Sponsors Shanghai Pharmaceuticals Holding

Most Recent Events

13 Dec 2023 Status changed from not yet recruiting to recruiting.
23 Nov 2023 Planned initiation date changed from 30 Oct 2023 to 30 Dec 2023.
23 Aug 2023 Planned initiation date changed from 30 Jun 2023 to 30 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com